Current Approaches to the Choice of Basic Therapy for Mild Persistent Bronchial Asthma in Children
Objective of the Study: improving the treatment of mild persistent bronchial asthma based on the development of differential program for antiinflammatory therapy. Of 120 children we have formed 3 groups depending on the effective basic therapy (leukotrien modifier, fluticasone propionate or their combination), which made it possible to achieve control of the disease.
Results. The highest concentrations of leukotrienes in blood serum were observed in children of the 3rd group, they were higher even after treatment, than in children from the control group. At the level of leukotrienes from 500 to 1000 pg/ml
chances of achieving bronchial asthma control using leukotrien modifier were 5.9 times higher compared with inhaled glucocorticosteroids (CI95% 2.01–18.2). And when the level of leukotrienes (C4/D4/E4) exceeded 1000 pg/ml, combination therapy is more effective than treatment with leukotrien modifier (odds ratio (OR) = 6.7; CI95% 2.5–17.8) and fluticasone propionate (OR = 83.3; CI95% 9.9–667.9).
Conclusions. Leukotrien modifier as monotherapy is indicated to 6–7-year-old children with mild persistent bronchial asthma and serum levels of leukotrienes from 500 to 1000 pg/ml.
At the level of leukotrienes below 500 pg/ml it is advisable to administer fluticasone propionate, above 1000 pg/ml — combination of leukotrien modifier and inhaled corticosteroid.
Hlobal'naya stratehyya lechenyya y profylaktyky bronkhyal'noy astmyi. (Peresmotr 2007 h.). – M. : Atmosfera, 2008. – 108 s.
Knyazheskaya N. P. Prymenenye antahonystov leykotryenovyikh retseptorov v dlytel'noy terapyy bol'nyikh bronkhyal'noy astmoy / N. P. Knyazheskaya // Ukr. pul'monol. zhurn. – 2011. – # 1. – S. 58–60.
Monoharova N. E. Uluchshenye rezul'tatov lechenyya bol'nyikh s bronkhyal'noy astmoy na fone lechenyya montelukastom / N. E. Monoharova // Astma ta alerhiya. – 2013. – # 1. – 71–76.
Okhotnykova E. N. Osobennosty techenyya y lechenyya bronkhyal'noy astmyi u detey ranneho vozrasta / E. N. Okhotnykova // Sovr. pedyatryya. – 2009. – # 2 (24). – S. 32–39.
Pukhlyk B. M. Dovidnyk z alerholohiyi / B. M. Pukhlyk. – K. : TOV «Doktor-Media», 2011. – 28 s.
Chernyisheva O. E. Sovremennyie predstavlenyya o patoheneze bronkhyal'noy astmyi / O. E. Chernyisheva, E. Y. Yulysh // Sovr. pedyatryya. – 2010. – # 2 (30). – S. 67–71.
Cowan D. C. Effects of steroid therapy of inflammatory cell subtypes in asthma / D. C. Cowan, J. O. Cowan, R. Palmay // Thorax. – Vol. 65, N 5. – 2010. – P. 384–390.
Global strategy for the diagnosis and management of asthma in children 5 years and younger / S. E. Pedersen, S. S. Hurd, R. F. Lemanske // Pediatr. Pulmonol. – 2011. – Vol. 46. – P. 1–17.
International consensus on (ICON) pediatric asthma / N. G. Papadopoulos, H. Arakawa, K. H. Carlsen [et al.] // Allergy. – 2012. – Vol. 67 (8). – P. 976–997.
Japanese guideline for childhood asthma / T. Nishimuta, N. Kondo, Y. Hamasaki [et al.] // Allergol. Int. – 2011. – Vol. 60 (2). – P. 147–149.
Montelukast more than a cysteinyl leukotriene receptor antagonist? / G. R. Tintinger, C. Feldman, A. J. Theron [et al.] // The Scientific World J. – 2010. – Vol. 10. – P. 2403–2413.
Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma Alessandra Scaparrotta, Sabrina Di Pillo, Marina Attanasi [et. al.] // Multidiscip Respir Medicine.- 2012. – Vol. 7(1). – P. 13-21.
Montuschi P. Role of Leukotrienes and Leukotriene Modifiers in Asthma / P. Montuschi // Pharmaceuticals. – 2010. – Vol. 3, N 6. – P. 1792–1811.
Role of Leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity / Ayse Baccioglu, Arzu Yorgancioglu, Cemal Cingi [et. al.] // J. Med. Updates. – 2013. – Vol. 3 (1). – P. 34–39.
Szefler S. J. Lessons learned from variation in response to therapy in clinical trials / S. J. Szefler, R. J. Martin // J. Allergy Clin. Immunol. – 2010. – Vol. 125, N 2. – P. 285–292.
Copyright (c) 2016 CHILD`S HEALTH
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2019